NEUROTOX: Two Dosages of Type A Botulinic Toxin in Neurogenic Overactive Bladder

University Hospital, Rouen

Status and phase: Terminated; Phase 2

Conditions: Overactive Bladder

Treatments: Drug: type A botulinum toxin

Study type: Interventional

Funder types: Other

Identifiers

NCT00213577

2003/112/HP

Details and patient eligibility

About

The purpose of this study is to determine the efficacy and tolerance of 2 dosages (750 versus 500 units) of the Dysport type A botulinic toxin for patient suffering from neurogenic urinary incontinence by an overactive bladder and the failure of anticholinergic drugs.

Enrollment: 80 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Neurogenic urinary incontinence with urodynamic overactivity resistant to anticholinergic

Exclusion criteria

• Pregnancy
• Bladder cancer
• Symptomatic urinary infection

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind